Popular on Rezul
- B&B Launches Revamped Services Page on Additions and Home Renovations in Denver, CO
- Don Barnhart Nominated for Best Comedian and Delirious Comedy Club Nominated for Best Comedy Club in Las Vegas
- Dr. Joon W. Park Publishes Groundbreaking Clinical Research on Optimizing Single Implant Placement in Healed Sites
- Actionstep Debuts Legal Accounting, Introduces Capture and Builder Products
- RX-Plumbing & Drain Announces New Location in Sugar Hill, GA
- Airborne Locksmith Introduces Advanced High-Security Locks to Combat Increasing Break-Ins in Houston
- LAIIER Joins US Proptech Council
- Positive Clinical Results with Promising Gene Therapy Treatment for Late Stage Lung Cancer; Life-Changing Developments for Cancer & Diabetes: GNPX
- Unmissable Lease-to-Own Opportunity: Luxury Home in Rotonda West with a Thriving Airbnb Business
- Phoenix Theory Unveils Revolutionary Perspective on Quantum Entanglement, Causality and Particle Physics
Similar on Rezul
- College Campus Safety: The Importance of Self Defense Keychains for Women
- CCHR Seeks Redress for Those Forcibly Held and Harmed in Behavioral Facilities
- DocVilla Introduces Best All-in-One Customizable Cloud-Based EHR Practice Management Software for Multi-Specialty and Small Practices
- Sycamore Hills Dentistry Welcomes the Yomi Robot: The Future of Dental Implant Surgery
- Cooking with Claudine Re-Launches in September with Fresh, Organic, and Gluten-Free Meal Delivery in the San Francisco Bay Area
- Dr. Seth Chambers Shares Journey to Success in Implant Dentistry on Unofficial Podcast's Summer Series: "Mind, Body, & Arches"
- Health is for EveryBODY™ Campaign Partners with Chip In™
- Melanated Cares Foundation to Host 2024 Annual Camping Retreat "Melanated Campout" Powered by Winnebago Industries Foundation
- Health is for EveryBODY™ Welcomes Ciba Health as a Sponsor
- Planned Spin-Out to Focus on Gene Therapy for Type 1 and 2 Diabetes in Parallel to Treatments for Late Stage Lung Cancer: Genprex: Stock Symbol: GNPX
NeuraWorx Partners with Corundum Neuroscience to Initiate Clinical Feasibility Study, Develop Innovative Neurological Disease Treatment
Rezul News/10677988
EXCELSIOR, Minn. - Rezul -- NeuraWorx Medical Technologies, Inc., a neurotechnology therapeutics company, announced today a partnership with prominent neuroscience venture builder and fund, Corundum Neuroscience. As part of the collaboration, Corundum will provide resources, including the initial investment in a NeuraWorx seed funding round, aimed at advancing product development and initiating a clinical feasibility study to explore the efficacy and safety of its Cerebrovascular Pacing SystemTM novel technology.
"Corundum Neuroscience exists to solve significant brain health challenges by discovering, funding and supporting companies building breakthrough technologies in neuroscience," said Liron Nunez Weissman, CEO of Corundum Neuroscience. "We see a significant market opportunity for NeuraWorx's technology and believe in its potential to revolutionize the treatments of neurological diseases and improve human health and lifespan."
NeuraWorx is developing the Cerebrovascular Pacing System, a first-in-class wearable neurostimulator, which leverages established bioelectronic principles to enhance the brain's glymphatic and cerebrovascular systems, aiming to enhance waste clearance for improved brain health.
"Approaches that modulate the brain's environment are creating new opportunities for improved brain function and we believe that NeuraWorx has a unique solution that could unlock this potential," said Josh Schulman, PhD, chief scientist of Corundum Neuroscience. "We're thrilled to partner with them on this study that aims to explore how their stimulation can impact the brain in ways that could lead to new treatments for brain injuries and diseases, as well as potentially impacting neurodegeneration in a range of brain states."
More on Rezul News
As a long-term partner, Corundum Neuroscience will support NeuraWorx as it continues to develop the Cerebrovascular Pacing System by providing access to Corundum Neuroscience's advanced technological projects, scientific expertise and strategic funding.
The upcoming clinical study will be a crucial step in understanding the potential of NeuraWorx's Cerebrovascular Pacing product, paving the way for future advancements in the treatment of central nervous system (CNS) disorders. Both companies are committed to pushing the boundaries of neuroscience to deliver life-changing solutions to improve the lives of patients worldwide. NeuraWorx intends to pursue indications for traumatic brain injury (TBI), Alzheimer's dementia and other CNS disorders, while also developing preventive solutions tailored for military personnel, athletes and a variety of medical applications.
"We are excited to work with Corundum Neuroscience, whose expertise and resources in the neuroscience field will be instrumental in advancing our technology," said Dr. Kip Ludwig, co-founder of NeuraWorx, associate professor at the University of Wisconsin-Madison and co-director of the Wisconsin Institute for Translational Neuroengineering.
"This partnership aligns perfectly with our mission to alleviate suffering and enhance quality of life by developing groundbreaking treatments and preventive solutions for CNS disorders," added Chris Minar, CEO at NeuraWorx.
For more information about NeuraWorx Medical Technologies, Inc., and its innovative approach, visit www.neuraworx.com. To learn more about Corundum Neuroscience and its initiatives, visit www.cnsfund.com.
About NeuraWorx
NeuraWorx Medical Technologies, Inc., is developing a Cerebrovascular Pacing SystemTM, as a first-in-class bioelectronic solution for enhancing cerebral spinal fluid flow and blood flow in the brain. Its products are intended to be for both preventative and therapeutic use, for traumatic brain injury (TBI), Alzheimer's dementia, and other CNS diseases. NeuraWorx was founded in Minnesota, shortly after its science was developed at the University of Wisconsin and the Mayo Clinic. For company updates and information, follow NeuraWorx on LinkedIn or visit: https://www.neuraworx.com
More on Rezul News
About Corundum Neuroscience
Corundum Neuroscience is a venture builder and fund advancing transformative neuroscience solutions from lab-to-life. The Corundum Neuroscience team combines deep domain expertise with a track record of venture-building success to accelerate neuroscience solutions across the entire innovation lifecycle. Taking a long-term investment approach, Corundum Neuroscience helps researchers, entrepreneurs and startups develop life-changing solutions that target specific disease areas and outcomes to enhance people's health, longevity, and quality of life. Founded by former Joy Ventures executives, Corundum Neuroscience launched in September 2023 and is headquartered in Herzliya, Israel.
For company updates and information, follow Corundum Neuroscience on LinkedIn or visit https://cnsfund.com.
"Corundum Neuroscience exists to solve significant brain health challenges by discovering, funding and supporting companies building breakthrough technologies in neuroscience," said Liron Nunez Weissman, CEO of Corundum Neuroscience. "We see a significant market opportunity for NeuraWorx's technology and believe in its potential to revolutionize the treatments of neurological diseases and improve human health and lifespan."
NeuraWorx is developing the Cerebrovascular Pacing System, a first-in-class wearable neurostimulator, which leverages established bioelectronic principles to enhance the brain's glymphatic and cerebrovascular systems, aiming to enhance waste clearance for improved brain health.
"Approaches that modulate the brain's environment are creating new opportunities for improved brain function and we believe that NeuraWorx has a unique solution that could unlock this potential," said Josh Schulman, PhD, chief scientist of Corundum Neuroscience. "We're thrilled to partner with them on this study that aims to explore how their stimulation can impact the brain in ways that could lead to new treatments for brain injuries and diseases, as well as potentially impacting neurodegeneration in a range of brain states."
More on Rezul News
- Luxury Real Estate Agent James Edmunds lists luxury beach home in the heart of Deerfield Beach
- Sycamore Hills Dentistry Welcomes the Yomi Robot: The Future of Dental Implant Surgery
- MGN Logistics, Inc. and Arvo A.I. Ltd Forge Game-Changing Partnership to Supercharge Freight Management!
- Daum Group Shares Tips to Help Sell Your Home this Fall
- Historic home in highly desirable Summit Hill neighborhood of St Paul
As a long-term partner, Corundum Neuroscience will support NeuraWorx as it continues to develop the Cerebrovascular Pacing System by providing access to Corundum Neuroscience's advanced technological projects, scientific expertise and strategic funding.
The upcoming clinical study will be a crucial step in understanding the potential of NeuraWorx's Cerebrovascular Pacing product, paving the way for future advancements in the treatment of central nervous system (CNS) disorders. Both companies are committed to pushing the boundaries of neuroscience to deliver life-changing solutions to improve the lives of patients worldwide. NeuraWorx intends to pursue indications for traumatic brain injury (TBI), Alzheimer's dementia and other CNS disorders, while also developing preventive solutions tailored for military personnel, athletes and a variety of medical applications.
"We are excited to work with Corundum Neuroscience, whose expertise and resources in the neuroscience field will be instrumental in advancing our technology," said Dr. Kip Ludwig, co-founder of NeuraWorx, associate professor at the University of Wisconsin-Madison and co-director of the Wisconsin Institute for Translational Neuroengineering.
"This partnership aligns perfectly with our mission to alleviate suffering and enhance quality of life by developing groundbreaking treatments and preventive solutions for CNS disorders," added Chris Minar, CEO at NeuraWorx.
For more information about NeuraWorx Medical Technologies, Inc., and its innovative approach, visit www.neuraworx.com. To learn more about Corundum Neuroscience and its initiatives, visit www.cnsfund.com.
About NeuraWorx
NeuraWorx Medical Technologies, Inc., is developing a Cerebrovascular Pacing SystemTM, as a first-in-class bioelectronic solution for enhancing cerebral spinal fluid flow and blood flow in the brain. Its products are intended to be for both preventative and therapeutic use, for traumatic brain injury (TBI), Alzheimer's dementia, and other CNS diseases. NeuraWorx was founded in Minnesota, shortly after its science was developed at the University of Wisconsin and the Mayo Clinic. For company updates and information, follow NeuraWorx on LinkedIn or visit: https://www.neuraworx.com
More on Rezul News
- Jenni Lee Launches Kona Houses For Sale, Offering Comprehensive Real Estate Services in Kona, Hawaii and Surrounding Areas
- Cooking with Claudine Re-Launches in September with Fresh, Organic, and Gluten-Free Meal Delivery in the San Francisco Bay Area
- TalentWell Launches Next Generation of AI-powered Talent Sourcing with Automated, Personalized Videos
- Just listed in Clear Lake, Minnesota!
- Dr. Seth Chambers Shares Journey to Success in Implant Dentistry on Unofficial Podcast's Summer Series: "Mind, Body, & Arches"
About Corundum Neuroscience
Corundum Neuroscience is a venture builder and fund advancing transformative neuroscience solutions from lab-to-life. The Corundum Neuroscience team combines deep domain expertise with a track record of venture-building success to accelerate neuroscience solutions across the entire innovation lifecycle. Taking a long-term investment approach, Corundum Neuroscience helps researchers, entrepreneurs and startups develop life-changing solutions that target specific disease areas and outcomes to enhance people's health, longevity, and quality of life. Founded by former Joy Ventures executives, Corundum Neuroscience launched in September 2023 and is headquartered in Herzliya, Israel.
For company updates and information, follow Corundum Neuroscience on LinkedIn or visit https://cnsfund.com.
Source: NeuraWorx Medical Technologies, Inc.
0 Comments
Latest on Rezul News
- The Misfits Magazine Makes it Debut
- A Comprehensive Relocation Services for Those Moving from Orlando to Las Vegas
- Oliver Sean's "Mama Taught Me (Dance Mix)" Featuring DJ Xquizit Hits #1 in Multiple Countries Within 24 Hours of Release
- Epic Fit Fest Celebrates Diversity, Wellness, and Community in Grand Prairie, Texas
- New Jersey Pediatric Neuroscience Institute Opens State-of-the-Art Pediatric Neuroscience Center in Hamilton, NJ
- Titan Pressure Washing Demonstrates Tile Roof Deep Cleaning With 9 Year Dirt Build-Up
- Black Women Talk Tech's 'Roadmap to Billions' Conference Debuts in Toronto – Empowering Black Women in Tech
- Cardiff Multifamily Property Sold by Apartment Realty Group
- Kaplan Morrell Named Exclusive Workers' Compensation Firm for Greeley Police Officers Association
- Hoffman Homes Unveils New Brand
- Hanover Area YMCA Academy of Early Learning Awarded ECHO Innovation Grant
- An Officer and Gentlewoman, LLC Hired as Public Relations Partner for The Annual Atlanta Fashion and Polo Classic
- New $68 Million Dollar Listing on Lake Minnetonka - Non MLS
- United Capital Group Highlights the Importance of Retainer Payments for Property Consultants
- Shanna Shryne Design: Redefining Luxury Interior Design
- 5 Reasons to Choose a Local Sonoma County Photographer
- Generative AI University and Small Business Results Unite to Help Entrepreneurs Optimize Marketing and Growth
- Costa Rica House 4 Sale Releases a Guide on Costa Rica Residency Through Investment
- United Capital Group Unveils Game-Changing Property Finance Services to Accelerate Business Success
- Income Property Organization Offers University Club Apartments